Key Clinical Message: Dulaglutide is a relatively unpopular GLP-1 receptor agonist used for weight loss. This case demonstrates that dulaglutide may be beneficial for weight loss in morbidly obese patients with multiple comorbidities after thoroughly evaluating its efficacy, benefits, and long-term adverse effects through clinical trials.
Abstract: We present a case of a 27-year-old ex-sumo wrestler with bipolar II disorder, morbid obesity, hypertension, Type 2 Diabetes Mellitus (DM), and a Body Mass Index (BMI) of 49.